 Angus Toland
Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 7 | 2026 | 1322 | 1.240 |
Why?
| | Meningioma | 2 | 2021 | 87 | 1.230 |
Why?
| | Meningeal Neoplasms | 2 | 2021 | 94 | 1.230 |
Why?
| | Glioma | 3 | 2026 | 426 | 0.930 |
Why?
| | Spinal Cord Neoplasms | 3 | 2023 | 41 | 0.880 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2024 | 54 | 0.840 |
Why?
| | Biomarkers, Tumor | 5 | 2025 | 1322 | 0.750 |
Why?
| | Chondrosarcoma | 1 | 2022 | 17 | 0.730 |
Why?
| | Fibroma | 1 | 2022 | 20 | 0.720 |
Why?
| | Mutation | 7 | 2026 | 4099 | 0.700 |
Why?
| | Osteosarcoma | 1 | 2022 | 76 | 0.690 |
Why?
| | Bone Neoplasms | 1 | 2022 | 256 | 0.610 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2025 | 119 | 0.380 |
Why?
| | Astrocytoma | 2 | 2024 | 129 | 0.360 |
Why?
| | DNA Methylation | 2 | 2026 | 683 | 0.280 |
Why?
| | Brain Diseases, Metabolic, Inborn | 1 | 2026 | 6 | 0.250 |
Why?
| | Lung Neoplasms | 3 | 2025 | 2642 | 0.250 |
Why?
| | Succinate Dehydrogenase | 1 | 2026 | 67 | 0.240 |
Why?
| | Malformations of Cortical Development | 1 | 2026 | 19 | 0.240 |
Why?
| | Muscle Spasticity | 1 | 2026 | 63 | 0.230 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2025 | 19 | 0.230 |
Why?
| | Folate Receptor 1 | 1 | 2025 | 17 | 0.230 |
Why?
| | Submandibular Gland | 1 | 2025 | 20 | 0.220 |
Why?
| | Nose Neoplasms | 1 | 2025 | 21 | 0.220 |
Why?
| | Interleukin-5 | 1 | 2025 | 39 | 0.220 |
Why?
| | Carcinosarcoma | 1 | 2025 | 23 | 0.220 |
Why?
| | Churg-Strauss Syndrome | 1 | 2025 | 27 | 0.220 |
Why?
| | Perivascular Epithelioid Cell Neoplasms | 1 | 2024 | 2 | 0.220 |
Why?
| | Immunohistochemistry | 3 | 2025 | 1718 | 0.220 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2025 | 84 | 0.210 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2024 | 19 | 0.210 |
Why?
| | Sequence Analysis, DNA | 2 | 2026 | 824 | 0.210 |
Why?
| | Humans | 32 | 2026 | 144957 | 0.210 |
Why?
| | Neuroblastoma | 1 | 2026 | 174 | 0.210 |
Why?
| | Adrenoleukodystrophy | 1 | 2024 | 8 | 0.210 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 55 | 0.210 |
Why?
| | Proof of Concept Study | 1 | 2024 | 85 | 0.210 |
Why?
| | Teratoma | 1 | 2025 | 120 | 0.210 |
Why?
| | Fatal Outcome | 1 | 2024 | 307 | 0.200 |
Why?
| | Anus Neoplasms | 1 | 2024 | 32 | 0.200 |
Why?
| | DNA Copy Number Variations | 2 | 2025 | 183 | 0.200 |
Why?
| | Neoplasm Grading | 2 | 2025 | 309 | 0.200 |
Why?
| | Drug Resistant Epilepsy | 1 | 2026 | 137 | 0.200 |
Why?
| | Cauda Equina | 1 | 2023 | 6 | 0.200 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 36 | 0.190 |
Why?
| | Lymphoproliferative Disorders | 1 | 2023 | 57 | 0.190 |
Why?
| | Carcinoma, Small Cell | 1 | 2023 | 173 | 0.190 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2024 | 75 | 0.190 |
Why?
| | Single-Cell Analysis | 2 | 2026 | 359 | 0.190 |
Why?
| | Polyomavirus | 1 | 2022 | 11 | 0.190 |
Why?
| | Polyomavirus Infections | 1 | 2022 | 29 | 0.180 |
Why?
| | Atlases as Topic | 1 | 2022 | 11 | 0.180 |
Why?
| | Nonlinear Optical Microscopy | 1 | 2022 | 1 | 0.180 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2025 | 988 | 0.180 |
Why?
| | Cells | 1 | 2022 | 25 | 0.180 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2024 | 264 | 0.180 |
Why?
| | Gangliosides | 1 | 2022 | 23 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 101 | 0.180 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 241 | 0.180 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 192 | 0.180 |
Why?
| | Central Nervous System Neoplasms | 1 | 2024 | 174 | 0.170 |
Why?
| | Peripheral Nerves | 1 | 2022 | 72 | 0.170 |
Why?
| | Organ Specificity | 1 | 2022 | 313 | 0.170 |
Why?
| | Neural Stem Cells | 1 | 2023 | 166 | 0.170 |
Why?
| | Brain Stem Neoplasms | 1 | 2022 | 87 | 0.170 |
Why?
| | Ependymoma | 1 | 2023 | 176 | 0.170 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2021 | 68 | 0.170 |
Why?
| | Sarcoma, Clear Cell | 1 | 2020 | 9 | 0.160 |
Why?
| | RNA Splicing | 1 | 2022 | 285 | 0.160 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2021 | 132 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2022 | 348 | 0.160 |
Why?
| | Papillomavirus Infections | 1 | 2024 | 345 | 0.150 |
Why?
| | Male | 15 | 2026 | 72406 | 0.150 |
Why?
| | Ovarian Neoplasms | 1 | 2025 | 586 | 0.150 |
Why?
| | DNA | 1 | 2026 | 1464 | 0.150 |
Why?
| | Cholecystitis | 1 | 2019 | 23 | 0.150 |
Why?
| | Neurons | 2 | 2025 | 1642 | 0.140 |
Why?
| | Tumor Suppressor Proteins | 1 | 2021 | 321 | 0.140 |
Why?
| | Antigens, Neoplasm | 1 | 2020 | 272 | 0.140 |
Why?
| | Transcriptome | 2 | 2022 | 1046 | 0.140 |
Why?
| | Needles | 1 | 2019 | 62 | 0.140 |
Why?
| | Hematologic Diseases | 1 | 2019 | 66 | 0.140 |
Why?
| | Brain | 4 | 2026 | 2941 | 0.140 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 337 | 0.140 |
Why?
| | Female | 14 | 2026 | 78376 | 0.130 |
Why?
| | Specimen Handling | 1 | 2019 | 186 | 0.130 |
Why?
| | Hematologic Neoplasms | 1 | 2019 | 162 | 0.120 |
Why?
| | Prognosis | 2 | 2026 | 4293 | 0.120 |
Why?
| | Histones | 1 | 2022 | 670 | 0.120 |
Why?
| | Prostatic Neoplasms | 1 | 2023 | 978 | 0.120 |
Why?
| | Influenza, Human | 1 | 2022 | 617 | 0.120 |
Why?
| | Survival Rate | 1 | 2020 | 2092 | 0.110 |
Why?
| | RNA | 1 | 2022 | 940 | 0.110 |
Why?
| | Alzheimer Disease | 1 | 2022 | 622 | 0.110 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2026 | 70 | 0.110 |
Why?
| | Child | 7 | 2026 | 22657 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1524 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 1141 | 0.110 |
Why?
| | Adult | 9 | 2026 | 40506 | 0.110 |
Why?
| | Infant, Newborn | 2 | 2024 | 6434 | 0.110 |
Why?
| | Child, Preschool | 4 | 2026 | 11799 | 0.100 |
Why?
| | Adolescent | 6 | 2025 | 22453 | 0.100 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 1500 | 0.100 |
Why?
| | Melanoma | 1 | 2020 | 761 | 0.100 |
Why?
| | Molecular Typing | 1 | 2013 | 21 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2020 | 847 | 0.100 |
Why?
| | Escherichia coli Infections | 1 | 2013 | 129 | 0.090 |
Why?
| | Drug Resistance, Bacterial | 1 | 2013 | 199 | 0.090 |
Why?
| | Astrocytes | 2 | 2023 | 224 | 0.080 |
Why?
| | Neoplasms | 2 | 2026 | 2884 | 0.080 |
Why?
| | Middle Aged | 8 | 2026 | 35928 | 0.080 |
Why?
| | Microglia | 2 | 2022 | 269 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 735 | 0.070 |
Why?
| | Mice | 5 | 2025 | 18365 | 0.070 |
Why?
| | Escherichia coli | 1 | 2013 | 855 | 0.070 |
Why?
| | Infant | 4 | 2026 | 10039 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3550 | 0.060 |
Why?
| | Succinic Acid | 1 | 2026 | 42 | 0.060 |
Why?
| | Tissue Array Analysis | 1 | 2025 | 50 | 0.060 |
Why?
| | Maytansine | 1 | 2025 | 18 | 0.060 |
Why?
| | CpG Islands | 1 | 2026 | 165 | 0.060 |
Why?
| | Paracrine Communication | 1 | 2025 | 67 | 0.060 |
Why?
| | Vagus Nerve | 1 | 2025 | 91 | 0.060 |
Why?
| | Angiomyolipoma | 1 | 2024 | 21 | 0.050 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2024 | 36 | 0.050 |
Why?
| | Eye Neoplasms | 1 | 2024 | 30 | 0.050 |
Why?
| | Acetyl-CoA C-Acyltransferase | 1 | 2023 | 2 | 0.050 |
Why?
| | Immunoconjugates | 1 | 2025 | 137 | 0.050 |
Why?
| | Animals | 5 | 2025 | 38109 | 0.050 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2025 | 193 | 0.050 |
Why?
| | Aged | 5 | 2025 | 25947 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2026 | 437 | 0.050 |
Why?
| | Anal Canal | 1 | 2024 | 102 | 0.050 |
Why?
| | Glutamic Acid | 1 | 2025 | 251 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2024 | 202 | 0.050 |
Why?
| | beta Catenin | 1 | 2025 | 253 | 0.050 |
Why?
| | Microscopy | 1 | 2024 | 156 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2026 | 550 | 0.050 |
Why?
| | Endothelium | 1 | 2022 | 119 | 0.040 |
Why?
| | Spectrum Analysis, Raman | 1 | 2022 | 41 | 0.040 |
Why?
| | Neuroglia | 1 | 2023 | 172 | 0.040 |
Why?
| | Pericytes | 1 | 2022 | 36 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2026 | 1465 | 0.040 |
Why?
| | Synapses | 1 | 2025 | 439 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2025 | 535 | 0.040 |
Why?
| | California | 1 | 2022 | 475 | 0.040 |
Why?
| | Biopsy | 1 | 2024 | 1077 | 0.040 |
Why?
| | Myelin Sheath | 1 | 2022 | 168 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2024 | 524 | 0.040 |
Why?
| | Young Adult | 3 | 2024 | 14126 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2024 | 629 | 0.040 |
Why?
| | Gallbladder | 1 | 2019 | 15 | 0.040 |
Why?
| | Cholelithiasis | 1 | 2019 | 36 | 0.040 |
Why?
| | Hemodilution | 1 | 2019 | 11 | 0.040 |
Why?
| | Choledocholithiasis | 1 | 2019 | 20 | 0.040 |
Why?
| | Cholecystectomy | 1 | 2019 | 59 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2024 | 749 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 17101 | 0.040 |
Why?
| | Cerebral Cortex | 1 | 2022 | 465 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2019 | 183 | 0.030 |
Why?
| | Ecosystem | 1 | 2023 | 589 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2025 | 2499 | 0.030 |
Why?
| | Disease Progression | 1 | 2025 | 2852 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3415 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2024 | 8279 | 0.030 |
Why?
| | Bone Marrow | 1 | 2019 | 306 | 0.030 |
Why?
| | Lymphocytes | 1 | 2019 | 382 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2022 | 877 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2022 | 870 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1495 | 0.030 |
Why?
| | Risk Assessment | 1 | 2026 | 3676 | 0.030 |
Why?
| | Hippocampus | 1 | 2022 | 967 | 0.030 |
Why?
| | Transcription Factors | 1 | 2024 | 1742 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1135 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 1990 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2023 | 2832 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2025 | 11695 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3164 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2023 | 2050 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1407 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2022 | 1786 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1982 | 0.030 |
Why?
| | Germany | 1 | 2013 | 138 | 0.020 |
Why?
| | Chronic Disease | 1 | 2019 | 1813 | 0.020 |
Why?
| | Lung | 1 | 2025 | 4109 | 0.020 |
Why?
| | Risk Factors | 1 | 2026 | 10792 | 0.020 |
Why?
| | Escherichia coli Proteins | 1 | 2013 | 206 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2019 | 927 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 1915 | 0.010 |
Why?
| | United States | 1 | 2013 | 15988 | 0.010 |
Why?
|
|
Toland's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|